Human HAD phosphatases: Structure, mechanism, and roles in health and disease

FEBS Journal

Volumn 280, Issue 2, 2013, Pages 549-571

  Seifried, Annegrit ^a   Schultz, Jörg ^b   Gohla, Antje ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

aspartyl transferase; cancer; cardiovascular disease; HAD phosphatase; metabolism; neurological disease; Rossmann fold

Indexed keywords

ASPARTIC ACID; CYTOSOLIC 5' NUCLEOTIDASE 1A; CYTOSOLIC 5' NUCLEOTIDASE 1B; CYTOSOLIC 5' NUCLEOTIDASE 3; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 2; EYES ABSENT PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HALOACID DEHALOGENASE PHOSPHATASE; HYDROLASE; INTRACELLULAR 5' NUCLEOTIDASE; LIPID; MAGNESIUM; NUCLEOPHILE; PHOSPHOASPARTYL TRANSFERASE; PHOSPHOMANNOMUTASE; PHOSPHOMANNOMUTASE 2; PHOSPHOSERINE AMINOTRANSFERASE 1; PHOSPHOSERINE PHOSPHATASE; POLYNUCLEOTIDE 5' HYDROXYL KINASE; RNA POLYMERASE II; SMALL C TERMINAL DOMAIN PHOSPHATASE; UNCLASSIFIED DRUG; UVOMORULIN;

AMINO ACID SEQUENCE; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CATALYSIS; CRYSTALLOGRAPHY; DEPHOSPHORYLATION; DNA DAMAGE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME POLYMORPHISM; ENZYME SPECIFICITY; ENZYME STABILITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COMPLEMENTATION; GENETIC CONSERVATION; GENETIC DISORDER; GENETIC VARIABILITY; HAD GENE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MOLECULAR MECHANICS; MOLECULAR WEIGHT; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEQUENCE ALIGNMENT; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; FEMALE; HUMANS; HYDROLASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASES; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84872817040     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08633.x     Document Type: Review

References (115)

1. Koonin EV, &, Tatusov RL, (1994) Computer analysis of bacterial haloacid dehalogenases defines a large superfamily of hydrolases with diverse specificity. Application of an iterative approach to database search. J Mol Biol 244, 125-132.
2. Allen KN, &, Dunaway-Mariano D, (2009) Markers of fitness in a successful enzyme superfamily. Curr Opin Struct Biol 19, 658-665.
3. Aravind L, Galperin MY, &, Koonin EV, (1998) The catalytic domain of the P-type ATPase has the haloacid dehalogenase fold. Trends Biochem Sci 23, 127-129.
4. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, &, Mustelin T, (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699-711.
5. Tonks NK, (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7, 833-846.
6. Barford D, Das AK, &, Egloff MP, (1998) The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu Rev Biophys Biomol Struct 27, 133-164.
7. Shi Y, (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139, 468-484.
8. Yeo M, Lin PS, Dahmus ME, &, Gill GN, (2003) A novel RNA polymerase II C-terminal domain phosphatase that preferentially dephosphorylates serine 5. J Biol Chem 278, 26078-26085.
9. Archambault J, Pan G, Dahmus GK, Cartier M, Marshall N, Zhang S, Dahmus ME, &, Greenblatt J, (1998) FCP1, the RAP74-interacting subunit of a human protein phosphatase that dephosphorylates the carboxyl-terminal domain of RNA polymerase IIO. J Biol Chem 273, 27593-27601.
10. Tootle TL, Silver SJ, Davies EL, Newman V, Latek RR, Mills IA, Selengut JD, Parlikar BE, &, Rebay I, (2003) The transcription factor Eyes absent is a protein tyrosine phosphatase. Nature 426, 299-302.
11. Li X, Oghi KA, Zhang J, Krones A, Bush KT, Glass CK, Nigam SK, Aggarwal AK, Maas R, Rose DW, et al. (2003) Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 426, 247-254.
12. Rayapureddi JP, Kattamuri C, Steinmetz BD, Frankfort BJ, Ostrin EJ, Mardon G, &, Hegde RS, (2003) Eyes absent represents a class of protein tyrosine phosphatases. Nature 426, 295-298.
13. Moorhead GB, Trinkle-Mulcahy L, &, Ulke-Lemee A, (2007) Emerging roles of nuclear protein phosphatases. Nat Rev Mol Cell Biol 8, 234-244.
14. Burroughs AM, Allen KN, Dunaway-Mariano D, &, Aravind L, (2006) Evolutionary genomics of the HAD superfamily: understanding the structural adaptations and catalytic diversity in a superfamily of phosphoesterases and allied enzymes. J Mol Biol 361, 1003-1034.
15. Wang W, Kim R, Jancarik J, Yokota H, &, Kim SH, (2001) Crystal structure of phosphoserine phosphatase from Methanococcus jannaschii, a hyperthermophile, at 1.8 A resolution. Structure 9, 65-71.
16. Kim HY, Heo YS, Kim JH, Park MH, Moon J, Kim E, Kwon D, Yoon J, Shin D, Jeong EJ, et al. (2002) Molecular basis for the local conformational rearrangement of human phosphoserine phosphatase. J Biol Chem 277, 46651-46658.
17. Allen KN, &, Dunaway-Mariano D, (2004) Phosphoryl group transfer: evolution of a catalytic scaffold. Trends Biochem Sci 29, 495-503.
18. Peisach E, Selengut JD, Dunaway-Mariano D, &, Allen KN, (2004) X-ray crystal structure of the hypothetical phosphotyrosine phosphatase MDP-1 of the haloacid dehalogenase superfamily. Biochemistry 43, 12770-12779.
19. Zhang Y, Kim Y, Genoud N, Gao J, Kelly JW, Pfaff SL, Gill GN, Dixon JE, &, Noel JP, (2006) Determinants for dephosphorylation of the RNA polymerase II C-terminal domain by Scp1. Mol Cell 24, 759-770.
20. Kamenski T, Heilmeier S, Meinhart A, &, Cramer P, (2004) Structure and mechanism of RNA polymerase II CTD phosphatases. Mol Cell 15, 399-407.
21. Bernstein NK, Williams RS, Rakovszky ML, Cui D, Green R, Karimi-Busheri F, Mani RS, Galicia S, Koch CA, Cass CE, et al. (2005) The molecular architecture of the mammalian DNA repair enzyme, polynucleotide kinase. Mol Cell 17, 657-670.
22. Jung SK, Jeong DG, Chung SJ, Kim JH, Park BC, Tonks NK, Ryu SE, &, Kim SJ, (2010) Crystal structure of ED-Eya2: insight into dual roles as a protein tyrosine phosphatase and a transcription factor. FASEB J 24, 560-569.
23. Almo SC, Bonanno JB, Sauder JM, Emtage S, Dilorenzo TP, Malashkevich V, Wasserman SR, Swaminathan S, Eswaramoorthy S, Agarwal R, et al. (2007) Structural genomics of protein phosphatases. J Struct Funct Genomics 8, 121-140.
24. Lu Z, Wang L, Dunaway-Mariano D, &, Allen KN, (2009) Structure-function analysis of 2-keto-3-deoxy-D-glycero-D-galactonononate-9- phosphate phosphatase defines specificity elements in type C0 haloalkanoate dehalogenase family members. J Biol Chem 284, 1224-1233.
25. Gohla A, Birkenfeld J, &, Bokoch GM, (2005) Chronophin, a novel HAD-type serine protein phosphatase, regulates cofilin-dependent actin dynamics. Nat Cell Biol 7, 21-29.
26. Rinaldo-Matthis A, Rampazzo C, Reichard P, Bianchi V, &, Nordlund P, (2002) Crystal structure of a human mitochondrial deoxyribonucleotidase. Nat Struct Biol 9, 779-787.
27. Lahiri SD, Zhang G, Dunaway-Mariano D, &, Allen KN, (2006) Diversification of function in the haloacid dehalogenase enzyme superfamily: the role of the cap domain in hydrolytic phosphoruscarbon bond cleavage. Bioorg Chem 34, 394-409.
28. Wang L, Huang H, Nguyen HH, Allen KN, Mariano PS, &, Dunaway-Mariano D, (2010) Divergence of biochemical function in the HAD superfamily: D-glycero-D-manno-heptose-1,7-bisphosphate phosphatase (GmhB). Biochemistry 49, 1072-1081.
29. Collet JF, Stroobant V, &, Van Schaftingen E, (1999) Mechanistic studies of phosphoserine phosphatase, an enzyme related to P-type ATPases. J Biol Chem 274, 33985-33990.
30. Ridder IS, &, Dijkstra BW, (1999) Identification of the Mg2+-binding site in the P-type ATPase and phosphatase members of the HAD (haloacid dehalogenase) superfamily by structural similarity to the response regulator protein CheY. Biochem J, 339 (Pt 2), 223-226.
31. Bailey TL, &, Elkan C, (1994) Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 2, 28-36.
32. Virshup DM, &, Shenolikar S, (2009) From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 33, 537-545.
33. Quental R, Moleirinho A, Azevedo L, &, Amorim A, (2010) Evolutionary history and functional diversification of phosphomannomutase genes. J Mol Evol 71, 119-127.
34. Force A, Lynch M, Pickett FB, Amores A, Yan YL, &, Postlethwait J, (1999) Preservation of duplicate genes by complementary, degenerative mutations. Genetics 151, 1531-1545.
35. Kerk D, Templeton G, &, Moorhead GB, (2008) Evolutionary radiation pattern of novel protein phosphatases revealed by analysis of protein data from the completely sequenced genomes of humans, green algae, and higher plants. Plant Physiol 146, 351-367.
36. Kim Y, Gentry MS, Harris TE, Wiley SE, Lawrence JC Jr, &, Dixon JE, (2007) A conserved phosphatase cascade that regulates nuclear membrane biogenesis. Proc Nat Acad Sci USA 104, 6596-6601.
37. Newman JW, Morisseau C, Harris TR, &, Hammock BD, (2003) The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Nat Acad Sci USA 100, 1558-1563.
38. Rebay I, Silver SJ, &, Tootle TL, (2005) New vision from Eyes absent: transcription factors as enzymes. Trends Genet 21, 163-171.
39. Csaki LS, &, Reue K, (2010) Lipins: multifunctional lipid metabolism proteins. Annu Rev Nutr 30, 257-272.
40. Ghosh A, Shuman S, &, Lima CD, (2008) The structure of Fcp1, an essential RNA polymerase II CTD phosphatase. Mol Cell 32, 478-490.
41. Zheng H, Ji C, Gu S, Shi B, Wang J, Xie Y, &, Mao Y, (2005) Cloning and characterization of a novel RNA polymerase II C-terminal domain phosphatase. Biochem Biophys Res Commun 331, 1401-1407.
42. Amberger J, Bocchini C, &, Hamosh A, (2011) A new face and new challenges for Online Mendelian Inheritance in Man (OMIM(R)). Hum Mutat 32, 564-567.
43. Samuels ME, &, Rouleau GA, (2011) The case for locus-specific databases. Nat Rev Genet 12, 378-379.
44. Varon R, Gooding R, Steglich C, Marns L, Tang H, Angelicheva D, Yong KK, Ambrugger P, Reinhold A, Morar B, et al. (2003) Partial deficiency of the C-terminal-domain phosphatase of RNA polymerase II is associated with congenital cataracts facial dysmorphism neuropathy syndrome. Nat Genet 35, 185-189.
45. Yeo M, Lee SK, Lee B, Ruiz EC, Pfaff SL, &, Gill GN, (2005) Small CTD phosphatases function in silencing neuronal gene expression. Science 307, 596-600.
46. Zhang M, Liu J, Kim Y, Dixon JE, Pfaff SL, Gill GN, Noel JP, &, Zhang Y, (2010) Structural and functional analysis of the phosphoryl transfer reaction mediated by the human small C-terminal domain phosphatase, Scp1. Protein Sci 19, 974-986.
47. Zhang M, Cho EJ, Burstein G, Siegel D, &, Zhang Y, (2011) Selective inactivation of a human neuronal silencing phosphatase by a small molecule inhibitor. ACS Chem Biol 6, 511-519.
48. Wu Y, Evers BM, &, Zhou BP, (2009) Small C-terminal domain phosphatase enhances snail activity through dephosphorylation. J Biol Chem 284, 640-648.
49. Sapkota G, Knockaert M, Alarcon C, Montalvo E, Brivanlou AH, &, Massague J, (2006) Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J Biol Chem 281, 40412-40419.
50. Wrighton KH, Willis D, Long J, Liu F, Lin X, &, Feng XH, (2006) Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-beta signaling. J Biol Chem 281, 38365-38375.
51. Kashuba VI, Li J, Wang F, Senchenko VN, Protopopov A, Malyukova A, Kutsenko AS, Kadyrova E, Zabarovska VI, Muravenko OV, et al. (2004) RBSP3 (HYA22) is a tumor suppressor gene implicated in major epithelial malignancies. Proc Nat Acad Sci USA 101, 4906-4911.
52. Branzei D, &, Foiani M, (2008) Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 9, 297-308.
53. Weinfeld M, Mani RS, Abdou I, Aceytuno RD, &, Glover JN, (2011) Tidying up loose ends: the role of polynucleotide kinase/phosphatase in DNA strand break repair. Trends Biochem Sci 36, 262-271.
54. Diderich K, Alanazi M, &, Hoeijmakers JH, (2011) Premature aging and cancer in nucleotide excision repair-disorders. DNA Repair 10, 772-780.
55. El-Khamisy SF, (2011) To live or to die: a matter of processing damaged DNA termini in neurons. EMBO Mol Med 3, 78-88.
56. Lord CJ, &, Ashworth A, (2012) The DNA damage response and cancer therapy. Nature 481, 287-294.
57. Dobson CJ, &, Allinson SL, (2006) The phosphatase activity of mammalian polynucleotide kinase takes precedence over its kinase activity in repair of single strand breaks. Nucleic Acids Res 34, 2230-2237.
58. Shen J, Gilmore EC, Marshall CA, Haddadin M, Reynolds JJ, Eyaid W, Bodell A, Barry B, Gleason D, Allen K, et al. (2010) Mutations in PNKP cause microcephaly, seizures and defects in DNA repair. Nat Genet 42, 245-249.
59. Freschauf GK, Karimi-Busheri F, Ulaczyk-Lesanko A, Mereniuk TR, Ahrens A, Koshy JM, Rasouli-Nia A, Pasarj P, Holmes CF, Rininsland F, et al. (2009) Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase. Cancer Res 69, 7739-7746.
60. Cronin A, Mowbray S, Durk H, Homburg S, Fleming I, Fisslthaler B, Oesch F, &, Arand M, (2003) The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. Proc Nat Acad Sci USA 100, 1552-1557.
61. EnayetAllah AE, Luria A, Luo B, Tsai HJ, Sura P, Hammock BD, &, Grant DF, (2008) Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase. J Biol Chem 283, 36592-36598.
62. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gosele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, et al. (2008) Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40, 529-537.
63. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, &, Wong ND, (2004) Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109, 335-339.
64. Ingraham RH, Gless RD, &, Lo HY, (2011) Soluble epoxide hydrolase inhibitors and their potential for treatment of multiple pathologic conditions. Curr Med Chem 18, 587-603.
65. Imig JD, &, Hammock BD, (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discovery 8, 794-805.
66. Hunsucker SA, Mitchell BS, &, Spychala J, (2005) The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 107, 1-30.
67. Bianchi V, &, Spychala J, (2003) Mammalian 5′-nucleotidases. J Biol Chem 278, 46195-46198.
68. Rampazzo C, Miazzi C, Franzolin E, Pontarin G, Ferraro P, Frangini M, Reichard P, &, Bianchi V, (2010) Regulation by degradation, a cellular defense against deoxyribonucleotide pool imbalances. Mutat Res 703, 2-10.
69. Mathews CK, (2006) DNA precursor metabolism and genomic stability. FASEB J 20, 1300-1314.
70. Zanella A, Bianchi P, Fermo E, &, Valentini G, (2006) Hereditary pyrimidine 5′-nucleotidase deficiency: from genetics to clinical manifestations. Br J Haematol 133, 113-123.
71. Hunsucker SA, Spychala J, &, Mitchell BS, (2001) Human cytosolic 5′-nucleotidase I: characterization and role in nucleoside analog resistance. J Biol Chem 276, 10498-10504.
72. Galmarini CM, Jordheim L, &, Dumontet C, (2003) Role of IMP-selective 5′-nucleotidase (cN-II) in hematological malignancies. Leuk Lymphoma 44, 1105-1111.
73. Grant S, (1998) Ara-C: cellular and molecular pharmacology. Adv Cancer Res 72, 197-233.
74. Marinaki AM, Escuredo E, Duley JA, Simmonds HA, Amici A, Naponelli V, Magni G, Seip M, Ben-Bassat I, Harley EH, et al. (2001) Genetic basis of hemolytic anemia caused by pyrimidine 5′ nucleotidase deficiency. Blood 97, 3327-3332.
75. Mothet JP, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD, Rogawski MA, &, Snyder SH, (2000) d-serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor. Proc Nat Acad Sci USA 97, 4926-4931.
76. Tabatabaie L, Klomp LW, Berger R, &, de Koning TJ, (2010) l-Serine synthesis in the central nervous system: a review on serine deficiency disorders. Mol Genet Metab 99, 256-262.
77. Jaeken J, Detheux M, Fryns JP, Collet JF, Alliet P, &, Van Schaftingen E, (1997) Phosphoserine phosphatase deficiency in a patient with Williams syndrome. J Med Genet 34, 594-596.
78. Veiga-da-Cunha M, Collet JF, Prieur B, Jaeken J, Peeraer Y, Rabbijns A, &, Van Schaftingen E, (2004) Mutations responsible for 3-phosphoserine phosphatase deficiency. Eur J Hum Genet 12, 163-166.
79. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, et al. (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350.
80. Saxe JP, Wu H, Kelly TK, Phelps ME, Sun YE, Kornblum HI, &, Huang J, (2007) A phenotypic small-molecule screen identifies an orphan ligand-receptor pair that regulates neural stem cell differentiation. Chem Biol 14, 1019-1030.
81. Hawkinson JE, Acosta-Burruel M, &, Wood PL, (1996) The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur J Pharmacol 307, 219-225.
82. Jemc J, &, Rebay I, (2007) The eyes absent family of phosphotyrosine phosphatases: properties and roles in developmental regulation of transcription. Annu Rev Biochem 76, 513-538.
83. Jemc J, &, Rebay I, (2007) Identification of transcriptional targets of the dual-function transcription factor/phosphatase eyes absent. Dev Biol 310, 416-429.
84. Krishnan N, Jeong DG, Jung SK, Ryu SE, Xiao A, Allis CD, Kim SJ, &, Tonks NK, (2009) Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent. J Biol Chem 284, 16066-16070.
85. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, &, Rosenfeld MG, (2009) Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458, 591-596.
86. Okabe Y, Sano T, &, Nagata S, (2009) Regulation of the innate immune response by threonine-phosphatase of Eyes absent. Nature 460, 520-524.
87. Schonberger J, Wang L, Shin JT, Kim SD, Depreux FF, Zhu H, Zon L, Pizard A, Kim JB, Macrae CA, et al. (2005) Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nat Genet 37, 418-422.
88. Wayne S, Robertson NG, DeClau F, Chen N, Verhoeven K, Prasad S, Tranebjarg L, Morton CC, Ryan AF, Van Camp G, et al. (2001) Mutations in the transcriptional activator EYA4 cause late-onset deafness at the DFNA10 locus. Hum Mol Genet 10, 195-200.
89. Miller SJ, Lan ZD, Hardiman A, Wu J, Kordich JJ, Patmore DM, Hegde RS, Cripe TP, Cancelas JA, Collins MH, et al. (2010) Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis. Oncogene 29, 368-379.
90. Zhang L, Yang N, Huang J, Buckanovich RJ, Liang S, Barchetti A, Vezzani C, O'Brien-Jenkins A, Wang J, Ward MR, et al. (2005) Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res 65, 925-932.
91. Pandey RN, Rani R, Yeo EJ, Spencer M, Hu S, Lang RA, &, Hegde RS, (2010) The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Oncogene 29, 3715-3722.
92. Reichenberger KJ, Coletta RD, Schulte AP, Varella-Garcia M, &, Ford HL, (2005) Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res 65, 2668-2675.
93. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, &, Merlino G, (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10, 175-181.
94. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, et al. (2009) The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 119, 2678-2690.
95. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, &, Ford HL, (2009) Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest 119, 2663-2677.
96. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, &, Ford HL, (2012) Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 31, 552-562.
97. Grunewald S, (2009) The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta 1792, 827-834.
98. Veiga-da-Cunha M, Vleugels W, Maliekal P, Matthijs G, &, Van Schaftingen E, (2008) Mammalian phosphomannomutase PMM1 is the brain IMP-sensitive glucose-1,6-bisphosphatase. J Biol Chem 283, 33988-33993.
99. Matthijs G, Schollen E, Pardon E, Veiga-Da-Cunha M, Jaeken J, Cassiman JJ, &, Van Schaftingen E, (1997) Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat Genet 16, 88-92.
100. Matthijs G, Schollen E, Heykants L, &, Grunewald S, (1999) Phosphomannomutase deficiency: the molecular basis of the classical Jaeken syndrome (CDGS type Ia). Mol Genet Metab 68, 220-226.
101. Reue K, (2009) The lipin family: mutations and metabolism. Curr Opin Lipidol 20, 165-170.
102. Zeharia A, Shaag A, Houtkooper RH, Hindi T, de Lonlay P, Erez G, Hubert L, Saada A, de Keyzer Y, Eshel G, et al. (2008) Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet 83, 489-494.
103. Wiedmann S, Fischer M, Koehler M, Neureuther K, Riegger G, Doering A, Schunkert H, Hengstenberg C, &, Baessler A, (2008) Genetic variants within the LPIN1 gene, encoding lipin, are influencing phenotypes of the metabolic syndrome in humans. Diabetes 57, 209-217.
104. Loos RJ, Rankinen T, Perusse L, Tremblay A, Despres JP, &, Bouchard C, (2007) Association of lipin 1 gene polymorphisms with measures of energy and glucose metabolism. Obesity (Silver Spring) 15, 2723-2732.
105. Kang ES, Park SE, Han SJ, Kim SH, Nam CM, Ahn CW, Cha BS, Kim KS, &, Lee HC, (2008) LPIN1 genetic variation is associated with rosiglitazone response in type 2 diabetic patients. Mol Genet Metab 95, 96-100.
106. Ong KL, Leung RY, Wong LY, Cherny SS, Sham PC, Lam TH, Lam KS, &, Cheung BM, (2008) Association of a polymorphism in the lipin 1 gene with systolic blood pressure in men. Am J Hypertens 21, 539-545.
107. Fortpied J, Maliekal P, Vertommen D, &, Van Schaftingen E, (2006) Magnesium-dependent phosphatase-1 is a protein-fructosamine-6-phosphatase potentially involved in glycation repair. J Biol Chem 281, 18378-18385.
108. Wu R, Garland M, Dunaway-Mariano D, &, Allen KN, (2011) Homo sapiens dullard protein phosphatase shows a preference for the insulin-dependent phosphorylation site of lipin1. Biochemistry 50, 3045-3047.
109. Satow R, Kurisaki A, Chan TC, Hamazaki TS, &, Asashima M, (2006) Dullard promotes degradation and dephosphorylation of BMP receptors and is required for neural induction. Dev Cell 11, 763-774.
110. Roberts SJ, Stewart AJ, Schmid R, Blindauer CA, Bond SR, Sadler PJ, &, Farquharson C, (2005) Probing the substrate specificities of human PHOSPHO1 and PHOSPHO2. Biochim Biophys Acta 1752, 73-82.
111. Preumont A, Rzem R, Vertommen D, &, Van Schaftingen E, (2010) HDHD1, which is often deleted in X-linked ichthyosis, encodes a pseudouridine-5′- phosphatase. Biochem J 431, 237-244.
112. Maliekal P, Vertommen D, Delpierre G, &, Van Schaftingen E, (2006) Identification of the sequence encoding N-acetylneuraminate-9-phosphate phosphatase. Glycobiology 16, 165-172.
113. Jang YM, Kim DW, Kang TC, Won MH, Baek NI, Moon BJ, Choi SY, &, Kwon OS, (2003) Human pyridoxal phosphatase. Molecular cloning, functional expression, and tissue distribution. J Biol Chem 278, 50040-50046.
114. Li C, Liang YY, Feng XH, Tsai SY, Tsai MJ, &, O'Malley BW, (2008) Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. Mol Cell 31, 835-849.
115. Neff CD, Abkevich V, Packer JC, Chen Y, Potter J, Riley R, Davenport C, DeGrado Warren J, Jammulapati S, Bhathena A, et al. (2009) Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression. Mol Psychiatry 14, 621-630.